NASDAQ: FRTX - Fresh Tracks Therapeutics, Inc.

Altı ay boyunca karlılık: +26.35%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Fresh Tracks Therapeutics, Inc.


Şirket hakkında Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.

daha fazla ayrıntı
The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

IPO date 2022-09-08
ISIN US10802T2042
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.frtx.com
Цена ао 0.94
Günlük fiyat değişimi: -0.5319% (0.94)
Haftalık fiyat değişimi: -0.5319% (0.94)
Aylık fiyat değişimi: +0.5376% (0.93)
3 ayda fiyat değişimi: +24.67% (0.75)
Altı ayda fiyat değişimi: +26.35% (0.74)
Yıllık fiyat değişimi: +3.89% (0.9)
Yılbaşından bu yana fiyat değişimi: +26.35% (0.74)

Hafife alma

İsim Anlam Seviye
P/S 0.5982 10
P/BV 0.4823 10
P/E 0 0
EV/EBITDA 1.08 10
Toplam: 6.25

Yeterlik

İsim Anlam Seviye
ROA, % -49.15 0
ROE, % -57.34 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA 0 10
Toplam: 9.4

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 1.34 1
karlılık Ebitda, % -76.95 0
karlılık EPS, % -99.75 0
Toplam: 0.2



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Albert Nicholas Marchio II CEO, CFO, Secretary & Chairman 251.83k 1952 (73 yıl)
Aron Aizenstat M.B.A., P.M.P. Vice President of Corporate Development & Operations N/A
Ms. Sue Fattor Head of Human Resource N/A
Dr. James S. McElvain Ph.D. Interim Head of CMC Development N/A
Mr. Aaron Fox-Collis CPA VP of Finance & Chief Accounting Officer N/A

Adres: United States, Boulder. CO, 5777 Central Avenue - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.frtx.com